digoxin / Generic mfg. - LARVOL DELTA

Digoxin-induced ventricular fibrillation in undiagnosed Wolff-Parkinson-White syndrome: a clinical reminder - a letter to the editor. (PubMed, Ann Med Surg (Lond)) - No abstract available

Journal • Cardiovascular • CNS Disorders • Movement Disorders

Potentially inappropriate medications for patients with heart failure: a nationwide retrospective study from 2012 to 2022. (PubMed, J Pharm Policy Pract) - "Typical PIMs, such as benzodiazepine, anxiolytics medications, α-glucosidase inhibitors, thiazolidine, sulfonylurea, non-dihydropyridine calcium antagonists, digoxin, non-steroidal anti-inflammatory drugs, anticholinergics, and β2 agonists showed decreased prescription trends over the years (P for all trends <0.01)...Medical providers should contribute to optimising medications that minimise PIM administration to patients with HF. In the future, PIMs for patients with HF may need to be monitored as a safety indicator."

Journal • Retrospective data • Cardiovascular • Congestive Heart Failure • Heart Failure

From genetic causality to druggable targets: A multiomics framework identifies ZSCAN16 in gout pathogenesis. (PubMed, Sci Prog) - "Molecular docking confirmed ZSCAN16 as a structurally druggable target, showing high-affinity binding with known compounds (e.g. digoxin, binding energy = -9.6 kcal/mol).ConclusionsOur study identifies ZSCAN16 as a high-potential, druggable therapeutic target for gout, highlighting its genetic influence on specific immune cell activities during acute flares. Conversely, TRIM10 was deprioritized owing to substantial pleiotropic liabilities and poor chemical tractability. These findings suggest that ZSCAN16 could play a crucial role in the pathogenesis of gout and may provide a valuable lead for future drug discovery efforts."

Journal • Gout • Hematological Disorders • Immunology • Inflammatory Arthritis • Rheumatology

Herbal Remedies in Global Health Care: Classification, Toxicology, and Clinical Management. (PubMed, Ther Drug Monit) - "Comprehensive clinical management, patient education, and integration of traditional medicine into mainstream health care ensures safe, effective, and responsible use of herbal products."

Journal • Cardiovascular

Treating Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: Ablation or Medication (clinicaltrials.gov) - P=N/A | N=84 | Not yet recruiting | Sponsor: Nova Scotia Health Authority

New trial • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Heart Failure

A Study to Evaluate the Drug Interactions of HRS-7535 With Acetaminophen, Digoxin, Rosuvastatin, and Omeprazole in Obese or Overweight Subjects (clinicaltrials.gov) - P1 | N=40 | Not yet recruiting | Sponsor: Shandong Suncadia Medicine Co., Ltd.

New P1 trial • Genetic Disorders • Obesity

Minimum and Average Heart Rates in Pediatric Fontan Patients with Favorable Postoperative Outcomes: A Holter Monitoring Study. (PubMed, Pediatr Cardiol) - "Within the Fontan group, males and those on digoxin had lower minimum HRs, while heterotaxy was associated with higher minimum and average HRs. This is the first study to establish normative Holter HR data in pediatric Fontan patients and compare it to healthy counterparts. These findings suggest Fontan patients do not have significantly lower minimum heart rates and provide a valuable reference for clinical evaluation, supporting the need for larger, multicenter studies."

Journal • Cardiovascular • Pediatrics

Aldigo: Introducing Electronic Alerts to Reduce Inappropriate Digoxin Prescribing in Older Adults (clinicaltrials.gov) - P=N/A | N=5954 | Not yet recruiting | Sponsor: Consorci Sanitari de l'Alt Penedès i Garraf | Initiation date: Aug 2025 ➔ Dec 2025

Trial initiation date

Acute Supraventricular Tachycardia Revealing a Massive Saddle Pulmonary Embolism in a Young Male With Rhinovirus Infection: A Case Report. (PubMed, Cureus) - "During admission, he developed recurrent and refractory episodes of SVT, ultimately necessitating systemic thrombolysis with intravenous alteplase. Arrhythmia control was achieved with digoxin and bisoprolol, and follow-up echocardiography showed normalization of right ventricular function...This case highlights SVT as a rare but clinically significant presentation of acute PE, underscoring the importance of considering PE in patients with new-onset tachyarrhythmias and hemodynamic compromise. Early recognition and timely management are critical to preventing morbidity and mortality in such presentations."

Journal • Cardiovascular • Infectious Disease • Pulmonary Embolism • Respiratory Diseases • Venous Thromboembolism • Ventricular Tachycardia

Predicting Pharmacokinetics of Drugs in Patients with Heart Failure and Optimizing Their Dosing Strategies Using a Physiologically Based Pharmacokinetic Model. (PubMed, Pharmaceutics) - "Eight commonly used drugs (digoxin, furosemide, bumetanide, torasemide, captopril, valsartan, felodipine and midazolam) for treating HF and its comorbidities were selected. A PBPK model was successfully developed to predict the plasma concentration-time profiles of the eight tested drugs in both healthy subjects and HF patients. Furthermore, this model may also be applied to guide digoxin dose optimization for HF patients."

Journal • PK/PD data • Cardiovascular • Congestive Heart Failure • Heart Failure

A surrogate barrier model for high-throughput blood-brain barrier permeability prediction: integrating LLC-PK1-MOCK/MDR1 Cells and lysosomal trapping correction. (PubMed, Drug Deliv) - "Model integrity was assessed via transepithelial electrical resistance (TEER) and efflux functionality using control drugs (atenolol, digoxin). These results position the LLC-PK1-MOCK/MDR1 model as a reliable surrogate tool for early CNS drug screening, enabling rapid prioritization of candidates based on BBB penetration potential. Its integration into preclinical workflows promises to accelerate the development of therapeutics for neurological disorders."

Journal • CNS Disorders • ABCB1

Derivatization of Bufadienolides at Carbon-3 of the Steroid Core and Their Consequences for the Interaction with Na+,K+-ATPase. (PubMed, Int J Mol Sci) - "The model compounds included bufalin, bufalin-N-glucose, bufalin-O-glucose as well as digoxigenin, digoxigenin monodigitoxoside and digoxin...Similarly, the change from β- to α-anomer delocalizes the substituent precluding contacts with amino acid residues of the binding site. The presented mechanistic model of bufadienolide interactions with Na+,K+-ATPase helps to anticipate the consequences of modifications while designing derivatives with high anticancer activity but reduced cardiotoxicity."

Journal • Cardiovascular • Oncology

A Study in Healthy People to Test Whether BI 3000202 Affects How 2 Other Medicines (Rosuvastatin and Digoxin) Are Taken up in the Body (clinicaltrials.gov) - P1 | N=14 | Active, not recruiting | Sponsor: Boehringer Ingelheim | Recruiting ➔ Active, not recruiting

Enrollment closed

A Study in Healthy People to Test Whether BI 3000202 Affects How 2 Other Medicines (Rosuvastatin and Digoxin) Are Taken up in the Body (clinicaltrials.gov) - P1 | N=14 | Recruiting | Sponsor: Boehringer Ingelheim | Not yet recruiting ➔ Recruiting

Enrollment open

Study on Gastric Emptying Effect and Drug-Drug Interactions of GZR18 Injection (clinicaltrials.gov) - P1 | N=60 | Recruiting | Sponsor: Gan & Lee Pharmaceuticals. | Not yet recruiting ➔ Recruiting

Enrollment open • Genetic Disorders • Obesity

The controversies in the clinical management of β-blockers in acute heart failure induced by rapid atrial fibrillation: A narrative review. (PubMed, Am Heart J Plus) - "AF management guidelines generally recommend considering the addition of β-blockers when digoxin-like drugs (such as cedilanid) fail to effectively control the ventricular rate...This article systematically reviews the clinical management strategies under this guideline contradiction, including: (1) Different recommendations on ventricular rate control and the use of β-blockers in domestic and international guidelines for AF and HF; (2) A pooled analysis of relevant research evidence; (3) Application strategies of β-blockers (especially short-acting agents esmolol and landiolol) in the acute phase...Although some studies and consensus articles have focused on the management of rapid AF complicated by HF, there is currently a lack of systematic reviews on this issue. Therefore, the writing of this review has important academic value and clinical guiding significance, providing a reference for treatment decisions in this special population."

Journal • Review • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Heart Failure

Dicloxacillin and flucloxacillin inhibit hepatic uptake transporters - in vitro investigations and physiologically based pharmacokinetic modelling. (PubMed, bioRxiv) - "PBPK model simulations predicted no major change in rosuvastatin, a substrate for OATPs and BCRP, pharmacokinetics, when co-administered with dicloxacillin or flucloxacillin. Simulations with dicloxacillin and P-gp substrates dabigatran or digoxin also predicted limited inhibition of P-gp transport."

Journal • PK/PD data • Preclinical • Breast Cancer • Oncology • Solid Tumor • SLCO2B1

A DNAzyme amplifier-based immunoassay for small molecule detection. (PubMed, Analyst) - "We successfully detected small molecules, digoxin and folic acid, at picomolar levels through the proposed immunoassay. The immunoassay can specifically identify small molecules and enable their detection in complex sample matrices. This strategy provides a simple and sensitive approach to selectively detect small molecules, inspiring researchers to develop DNAzyme-based immunoassays with multiple functions."

Journal

Impact of digoxin on sinus rhythm restoration after catheter ablation of persistent atrial fibrillation and drug-refractory atrial tachyarrhythmia recurrence: A cohort study. (PubMed, J Int Med Res) - "No serious adverse effects occurred.ConclusionsDigoxin effectively restored sinus rhythm in selected patients experiencing recurrent atrial tachyarrhythmias after catheter ablation and ongoing medical therapy, particularly among those with smaller left atrial sizes. Further research is warranted to validate these findings and explore the underlying mechanisms."

Journal • Retrospective data • Atrial Fibrillation • Cardiovascular

Impact of Early Atrioventricular Nodal Blocker Use Post-Transcatheter Aortic Valve Replacement. (PubMed, Catheter Cardiovasc Interv) - "AV nodal blocker use within 48 h following TAVR was not associated with an increased rate of second-degree or higher AVB or PPM placement. These findings suggest that AV nodal blockers may be considered in the immediate post-TAVR period based on risk-benefit assessment."

Journal • Cardiovascular

Cardiac Glycosides Induce Immunogenic Changes in Myeloma Cells and Enhance the Efficacy of Monoclonal and Bispecific Antibody Therapy (ASH 2024) - P1 | "Therefore, the 4-1BB agonist Utomilumab is being tested in combination with CAR-T therapy (NCT 03704298).Here, to develop improved immune cell therapies for MM, we evaluated whether CGs enhances the anti-myeloma activity of monoclonal and bispecific antibodies by augmenting immune responses.Methods : Alterations of ICAM1 and 4-1BBL or SLAMF7 at the protein level were evaluated on two MM cell lines, AMO1 and KMS12PE, by flow cytometry after exposure to the CGs, i.e., digoxin, periplocin, ouabain, or hellebrin at minimally toxic concentrations.Treated MM cells were then co-cultured with immune effector cells from healthy donors together with elotuzumab (anti-SLAMF7 antibody) or teclistamab (BCMA bispecific antibody) in the presence or absence of low doses of CGs for 48 h. Thereafter, cytotoxic effects and effector cell activity were evaluated. Digoxin, a drug that can be used in clinical practice, also caused immunogenic changes in MM cells and enhanced the efficacy..."

Clinical • IO biomarker • Cardiovascular • Congestive Heart Failure • Heart Failure • Hematological Malignancies • Multiple Myeloma • Oncology • ICAM1 • IL2RA • SLAMF7

Phenotypic drug screening in human iPSC-derived neurons identifies modifiers of dipeptide Repeat-Induced toxicity and TDP-43 pathology in amyotrophic lateral sclerosis/frontotemporal dementia (ALS-MND 2025) - "Both screens independently identified cardiac glyco-sides—including the FDA-approved drug digoxin—as top hits (cell survival and neurite outgrowth Z-scores >2). In GR20- or PR20-treated neurons, digoxin significantly rescued survival and neurite outgrowth at nanomolar concentrations (n = 9–12 wells/condition; ρ < 0.0001). In bortezomib-treated neurons, digoxin rescued TDP-43 mislocalization (n = 3/condition; ρ < 0.05) and prevented cryptic exon inclusion in STMN2 and UNC13A (n = 3/condition; ρ < 0.01)."

Alzheimer's Disease • Amyotrophic Lateral Sclerosis • CNS Disorders • Dementia • Frontotemporal Lobar Degeneration • CLSPN, • NUP98 • STMN2 • TARDBP

Cardiac Glycosides Toxicity: Mechanisms and Mitigation Strategies in Recent Studies. (PubMed, Chem Biol Interact) - "Although their antitumor potential, exemplified by derivatives such as RX108 entering clinical trials, has renewed research interest, inherent cardiotoxicity remains a major safety concern...In addition, we examine their multi-organ toxicity profiles and corresponding clinical management strategies, with particular emphasis on digoxin-specific Fab antibodies. Another pivotal aspect of this review is a critical analysis of contemporary, rational structural modification strategies designed to decouple cardiotoxicity from therapeutic efficacy. By synthesizing these insights, this work aims to provide a foundational framework for overcoming the toxicity hurdles and advancing the repurposing of cardiac glycosides in precision oncology and other therapeutic areas."

Journal • Review • Cardiovascular • Oncology

Development of a Predictive Model for Acute Kidney Disease Following Stanford Type A Aortic Dissection Surgery (KIDNEY WEEK 2025) - "The AKD group demonstrated higher preoperative white blood cell counts (11.61×10 9 /L vs 11.35×10 9 /L, P =0.045), uric acid levels (339.00 μmol/L vs 335.00 μmol/L, P =0.013), and rates of renal malperfusion (64.9% vs 50.6%, P =0.014), AKI stage 3 (55.2% vs 10.9%, P <0.001), and prolonged mechanical ventilation (87.3% VS 67.4%, P <0.001), and lower postoperative digoxin use (21.0% vs 44.9%, P <0.001)...Conclusion Our nomogram enables early risk stratification to guide personalized management. Postoperative AKD independent predictors in Stanford Type A Aortic Dissection"

Predictive model • Surgery • Acute Kidney Injury • Nephrology • Renal Disease

Adherence to evidence-based practice in the treatment of digoxin poisoning in New South Wales, Australia. (PubMed, Br J Clin Pharmacol) - "The study shows that Australian clinical toxicologists began integrating new research findings before the 2020 guideline update, with significant improvement in adherence for digoxin poisoning cases post-August 2020."

Journal